Seres Therapeutics (MCRB) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Seres Therapeutics (NASDAQ: MCRB) in the last few weeks:

  • 11/14/2018 – Seres Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 11/10/2018 – Seres Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/9/2018 – Seres Therapeutics was given a new $16.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/8/2018 – Seres Therapeutics was given a new $15.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/6/2018 – Seres Therapeutics was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/2/2018 – Seres Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 10/28/2018 – Seres Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital.
  • 10/22/2018 – Seres Therapeutics is now covered by analysts at Chardan Capital. They set a “buy” rating and a $15.00 price target on the stock.
  • 10/2/2018 – Seres Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Shares of MCRB stock traded up $0.05 during midday trading on Monday, reaching $8.07. 70,600 shares of the company were exchanged, compared to its average volume of 133,225. Seres Therapeutics Inc has a 12 month low of $5.64 and a 12 month high of $11.35. The company has a market capitalization of $327.66 million, a price-to-earnings ratio of -3.65 and a beta of 0.61. The company has a current ratio of 2.04, a quick ratio of 2.04 and a debt-to-equity ratio of 0.85.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.03. The company had revenue of $9.06 million for the quarter, compared to the consensus estimate of $23.43 million. Seres Therapeutics had a negative net margin of 515.16% and a negative return on equity of 1,584.66%. On average, equities research analysts predict that Seres Therapeutics Inc will post -2.56 earnings per share for the current year.

In other news, insider John G. Aunins sold 14,279 shares of Seres Therapeutics stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $5.94, for a total value of $84,817.26. Following the transaction, the insider now owns 103,811 shares of the company’s stock, valued at approximately $616,637.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John G. Aunins sold 42,837 shares of Seres Therapeutics stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $7.64, for a total transaction of $327,274.68. Following the completion of the transaction, the insider now directly owns 146,648 shares in the company, valued at approximately $1,120,390.72. The disclosure for this sale can be found here. Insiders sold a total of 69,634 shares of company stock worth $526,006 in the last ninety days. Corporate insiders own 37.10% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in MCRB. ARK Investment Management LLC grew its stake in shares of Seres Therapeutics by 35.7% in the 2nd quarter. ARK Investment Management LLC now owns 3,266,428 shares of the biotechnology company’s stock worth $28,091,000 after purchasing an additional 859,705 shares during the last quarter. BlackRock Inc. grew its stake in shares of Seres Therapeutics by 23.0% in the 2nd quarter. BlackRock Inc. now owns 2,240,844 shares of the biotechnology company’s stock worth $19,272,000 after purchasing an additional 418,589 shares during the last quarter. Millennium Management LLC grew its stake in shares of Seres Therapeutics by 100.6% in the 2nd quarter. Millennium Management LLC now owns 172,173 shares of the biotechnology company’s stock worth $1,481,000 after purchasing an additional 86,348 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Seres Therapeutics by 104.9% in the 2nd quarter. Schroder Investment Management Group now owns 135,166 shares of the biotechnology company’s stock worth $1,244,000 after purchasing an additional 69,205 shares during the last quarter. Finally, Chicago Equity Partners LLC acquired a new position in shares of Seres Therapeutics in the 2nd quarter worth approximately $415,000. 79.86% of the stock is currently owned by institutional investors.

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Further Reading: How to Track your Portfolio in Google Finance

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply